Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Regeneron Pharmaceuticals, Inc. (REGN) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron Pharmaceuticals, Inc. (REGN) - free report >>
Image: Bigstock
Unity (UNX) Down on Disappointing Results From Wet AMD Study
Shares of Unity Biotechnology, Inc. (UBX - Free Report) plunged 53% after the company announced disappointing results from Part A of the phase II ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD).
The proof-of-concept phase II ENVISION study is a multi-center, randomized, double-masked, active-controlled study designed to evaluate the safety, tolerability, efficacy and durability of a repeat intravitreal injection of UBX1325 in patients with neovascular AMD evaluated through 24 weeks.
The study enrolled 51 patients actively treated with anti-VEGF who had a visual acuity deficit and residual retinal fluid.
Patients treated with UBX1325 had a mean change from baseline in CST of +87.3 µm at 24 weeks compared to +30.5 µm in the aflibercept control arm.
The company will assess and optimize its resource allocation for the future development of UBX1325 following a complete analysis of ENVISION results.
The company will provide an update on Part B of the ENVISION study and share 48-week data from the phase II BEHOLD DME study in April. UBX1325 showed strong evidence of biological activity and improvement in visual acuity in the DME study. Hence, the company plans to initiate a phase IIb study in the second half of this year.
.The disappointing results might dent Unity Biotechnology’s efforts to develop the candidate successfully.
Shares of Unity Biotechnology are down 35.8% in the year so far compared to the industry’s decline of 6.9%.
Image Source: Zacks Investment Research
Regeneron (REGN - Free Report) markets aflibercept under the brand name Eylea in collaboration with Bayer (BAYRY - Free Report) . The drug is a market leader in this space.
Eylea is Regeneron’s lead drug approved for various ophthalmology indications.
Regeneron records net product sales of Eylea in the United States and Bayer records net product sales of Eylea outside the United States. Regeneron records its share of profits/losses in connection with sales of Eylea outside the United States.
Unity Biotechnology currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.